Leap Therapeutics (LPTX) Trading 5.8% Higher

Shares of Leap Therapeutics Inc (NASDAQ:LPTX) traded up 5.8% during trading on Monday . The company traded as high as $2.44 and last traded at $2.38. 198,973 shares were traded during trading, a decline of 76% from the average session volume of 826,289 shares. The stock had previously closed at $2.25.

A number of analysts have commented on the stock. ValuEngine lowered shares of Leap Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, January 4th. Zacks Investment Research upgraded shares of Leap Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 16th. Finally, Raymond James reduced their target price on shares of Leap Therapeutics from $13.00 to $8.00 and set an “outperform” rating for the company in a research note on Wednesday, December 19th.

The stock has a market cap of $41.90 million, a price-to-earnings ratio of -0.70 and a beta of 2.29.

In related news, CEO Christopher Mirabelli purchased 571,428 shares of Leap Therapeutics stock in a transaction that occurred on Tuesday, February 5th. The stock was bought at an average price of $1.75 per share, for a total transaction of $999,999.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 58.70% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of Leap Therapeutics by 23.2% during the 3rd quarter. Vanguard Group Inc. now owns 256,268 shares of the company’s stock worth $1,997,000 after purchasing an additional 48,300 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Leap Therapeutics during the 4th quarter worth $28,000. Vanguard Group Inc raised its stake in Leap Therapeutics by 23.2% in the third quarter. Vanguard Group Inc now owns 256,268 shares of the company’s stock valued at $1,997,000 after buying an additional 48,300 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in Leap Therapeutics in the third quarter valued at about $111,000. Finally, Renaissance Technologies LLC raised its stake in Leap Therapeutics by 23.5% in the third quarter. Renaissance Technologies LLC now owns 138,868 shares of the company’s stock valued at $1,082,000 after buying an additional 26,401 shares during the last quarter. Institutional investors own 9.08% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Leap Therapeutics (LPTX) Trading 5.8% Higher” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2019/03/18/leap-therapeutics-lptx-trading-5-8-higher.html.

Leap Therapeutics Company Profile (NASDAQ:LPTX)

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.

See Also: Why Dividend Stocks May Be Right for You

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.